Compare CSR & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSR | OMER |
|---|---|---|
| Founded | 1970 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 894.8M |
| IPO Year | N/A | 2009 |
| Metric | CSR | OMER |
|---|---|---|
| Price | $64.43 | $11.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $70.20 | $32.50 |
| AVG Volume (30 Days) | 137.1K | ★ 2.6M |
| Earning Date | 02-17-2026 | 11-13-2025 |
| Dividend Yield | ★ 4.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $273,450,000.00 | N/A |
| Revenue This Year | $7.24 | N/A |
| Revenue Next Year | $2.63 | N/A |
| P/E Ratio | $35.23 | ★ N/A |
| Revenue Growth | ★ 5.72 | N/A |
| 52 Week Low | $52.76 | $2.95 |
| 52 Week High | $69.15 | $17.65 |
| Indicator | CSR | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 45.94 |
| Support Level | $63.41 | $11.45 |
| Resistance Level | $66.25 | $12.68 |
| Average True Range (ATR) | 1.37 | 0.72 |
| MACD | -0.15 | -0.25 |
| Stochastic Oscillator | 21.71 | 9.51 |
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.